Clinical Trial Update: The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effects of adding Interleukin-2 to anti-HIV therapy in HIV-positive patients with CD4 counts ≥350 cells/mm3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED